IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer
- Written by PR Newswire
SYDNEY, Nov. 21, 2022 /PRNewswire/ --
Highlights
- Clarity's fifth successful Investigational New Drug (IND) application with the United States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin
- A total of six products with both the diagnostic and therapeutic applications for SARTATE, SAR-bisPSMA and SAR...